🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Studying the Role of Circulating Tumor Cell Clusters in Patients With High-risk Early Breast Cancer, Study GALIA

RecruitingNAAges 18 Years - anyFemaleInstitute of Oncology Ljubljana
NCT07418125 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

CTCs, CTC clusters, and ctDNA may predict treatment response and survival in high-risk breast cancer, including IBC.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients with inflammatory breast cancer, regardless of cancer subtype (stage IIID) * Patients with non-inflammatory breast cancer: triple-negative and HER2+ subtypes, from stage IIB to IIIA-C * Adequate health status for neoadjuvant systemic treatment Exclusion Criteria: * Inflammatory breast cancer stage IV * Luminal A, luminal B subtypes of non-inflammatory breast cancer * Stages I-IIA breast cancer * Inability to understand or communicate in Slovenian * Inability to follow protocol instructions * Inappropriate health status for chemotherapy treatment * Primary treatment with surgery
💊

What it tests

  • Liquid biopsy
📍

Where

1 site
Institute of Oncology Ljubljana
Ljubljana, Slovenia
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy